Related Experiment Video
Updated: Aug 7, 2026

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
Nanotechnology-Enabled Targeted Protein Degradation: Strategies, Opportunities, and Challenges
Haoran Zhu1, Yijun Zhang1, Yuhua Ning1
1The MOE Key Laboratory of Spectrochemical Analysis & Instrumentation, the Key Laboratory of Chemical Biology of Fujian Province, State Key Laboratory of Physical Chemistry of Solid Surfaces, Department of Chemical Biology, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, China.
Targeted protein degradation (TPD) agents face delivery challenges. Nanotechnology integration (nano-TPD) overcomes these limitations, enabling new therapies for previously undruggable targets.
Area of Science:
- Biotechnology
- Nanomedicine
- Drug Delivery
Background:
- Targeted protein degradation (TPD) offers a novel therapeutic strategy by eliminating disease-causing proteins.
- Clinical translation of TPD agents is hindered by poor solubility, membrane permeability, and tissue selectivity.
- Nanotechnology presents a promising approach to overcome these physicochemical barriers.
Purpose of the Study:
- To review the integration of nanotechnology with targeted protein degradation (TPD).
- To highlight how nanoplatforms can address TPD delivery challenges.
- To discuss strategies for advancing nano-TPD for therapeutic applications.
Main Methods:
- Review of diverse nanoplatforms (lipid, polymeric, inorganic, biomimetic) for TPD.
- Analysis of design strategies: physical encapsulation, chemical conjugation, carrier-free self-assembly.
- Examination of nano-bio interface engineering for controlled cellular processes.
Main Results:
- Nanocarrier-assisted TPD improves degrader pharmacokinetics.
- Nanostructure-integrated TPD facilitates ternary complex formation.
- Engineered nano-bio interfaces enhance cellular uptake and intracellular trafficking.
Conclusions:
- Nano-TPD strategies effectively address TPD delivery challenges.
- Rational design and collaboration are key to overcoming translational hurdles.
- Nano-TPD holds significant potential for treating diseases with undruggable targets.
More Related Videos
07:22The Development and Application of Biophysical Assays for Evaluating Ternary Complex Formation Induced by Proteolysis Targeting Chimeras (PROTACS)
Published on: January 12, 2024
10:44Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Related Concept Videos
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Site-Targeted Drug Delivery Systems: Polymeric Carriers